By Fineline Cube Lupeng Pharmaceutical Ltd. announced the enrollment of the first patient in its global Phase 3 ROCKET-CLL trial (NCT07342478), evaluating rocbrutinib (LP-168), a novel fourth-generation Bruton’s tyrosine kinase (BTK) inhibitor, against pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL) who have received prior therapy with a covalent BTK inhibitor (cBTKi).
Trial Design & Enrollment
| Parameter | Detail |
|---|---|
| Trial Name | ROCKET-CLL (NCT07342478) |
| Phase | Phase 3 |
| Design | Randomized, open-label, multicenter |
| Patient Population | Adult patients with R/R CLL/SLL post cBTKi |
| Planned Enrollment | ~306 patients globally |
| Primary Endpoint | Progression-free survival (PFS) |
| Key Secondary Endpoints | Overall response rate (ORR), duration of response (DOR), safety profile |
| First Patient Enrolled | 21 May 2026 |
Drug Profile & Mechanism of Action
- Molecule: Rocbrutinib (LP-168) – fourth-generation oral BTK inhibitor
- Platform: Developed on Lupeng’s proprietary BeyondX platform
- Innovation: Combines covalent (irreversible) and non-covalent (reversible) binding mechanisms
- Target Coverage: Inhibits both wild-type and C481-mutant BTK
- Resistance Profile: Engineered to overcome multiple resistance mutations including C481X, T474X, and L528W
- Development Status: Best-in-class potential in post-cBTKi setting
Clinical Context & Competitive Landscape
| Aspect | Rocbrutinib (LP-168) | Pirtobrutinib | Other Next-Gen BTKis |
|---|---|---|---|
| Generation | Fourth | Third | Second/Third |
| Binding Mechanism | Dual (covalent + non-covalent) | Non-covalent only | Primarily covalent |
| C481 Mutation Coverage | Yes | Yes | Limited/None |
| Additional Mutations Targeted | C481X, T474X, L528W | Primarily C481 | Variable |
| Trial Design | Head-to-head vs. pirtobrutinib | Approved based on single-arm trials | Various |
The ROCKET-CLL trial represents one of the first direct head-to-head comparisons between next-generation BTK inhibitors in the post-covalent BTK inhibitor setting, where treatment options remain limited despite the high unmet medical need.
Market Impact & Development Outlook
- Global CLL Market: Projected to reach $8.2 billion by 2030, with next-generation BTK inhibitors representing the fastest-growing segment
- Patient Population: Approximately 30-40% of CLL patients develop resistance to covalent BTK inhibitors within 2-3 years of treatment initiation
- Competitive Advantage: Rocbrutinib’s dual-binding mechanism may provide superior efficacy against diverse resistance mutations compared to single-mechanism inhibitors
- Development Timeline: Full enrollment expected by Q2 2028, with top-line results anticipated in H2 2028
- Commercial Strategy: Lupeng is preparing for potential global regulatory submissions following successful trial completion
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, trial outcomes, and market potential for rocbrutinib. Actual results may differ materially due to risks including clinical trial outcomes, regulatory decisions, competitive developments, and market dynamics.-Fineline Info & Tech